Lung Cancer

Top Story

Low-dose olprinone reduces risk for atrial fibrillation after lung cancer surgery

July 28, 2015

The administration of olprinone continuously during lung cancer surgery reduced the risk for atrial fibrillation in patients with elevated preoperative B-type natriuretic peptide levels, according to study results.

“Continuous infusion of low-dose olprinone was found to be highly tolerable, and no significant adverse effects were observed,” Takashi Nojiri, MD, PhD, a general thoracic surgery staff surgeon at Osaka University Graduate School of Medicine in Japan, and colleagues wrote. “These findings indicate that low-dose olprinone is a preferred treatment option to prevent postoperative atrial fibrillation in high-risk patients undergoing non-cardiac surgery.”

In the Journals

Tivantinib, erlotinib improve PFS, not OS in advanced NSCLC

July 27, 2015
The addition of tivantinib to erlotinib did not improve OS in patients with advanced or metastatic nonsquamous non–small cell lung cancer, according to results of…
SupplementPublication Exclusive

Perspectives from ASCO 2015: A HemOnc Today Special Report

HemOnc Today, July 25, 2015
This year’s ASCO Annual Meeting featured the theme “Illumination and Innovation: Transforming Data into Learning.”As such, meeting organizers selected…
Mary Reid In the Journals

Smoking after lung cancer diagnosis reduces survival

July 20, 2015
Patients with lung cancer who quit smoking at or after their diagnosis had better survival than patients who continued using tobacco after diagnosis, according to study…
CME
Hematology Oncology Case Consults

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia.
More »
Meeting News Coverage Video
VIDEO: Advancements in immunotherapy drug combinations show promise for multiple cancer types

VIDEO: Advancements in immunotherapy drug combinations show promise for multiple cancer types

June 16, 2015
CHICAGO — Edward S. Kim, MD, chair of solid tumor oncology and investigational therapeutics at the Levine Cancer…
More »
CME
Immunotherapy Updates 2015: FOCUS on NSCLC

Immunotherapy Updates 2015: FOCUS on NSCLC

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
Takashi Nojiri In the Journals

Low-dose olprinone reduces risk for atrial fibrillation after lung cancer surgery

July 28, 2015
The administration of olprinone continuously during lung cancer surgery reduced the risk for atrial fibrillation in patients with elevated…
In the Journals

Tivantinib, erlotinib improve PFS, not OS in advanced NSCLC

July 27, 2015
The addition of tivantinib to erlotinib did not improve OS in patients with advanced or metastatic nonsquamous non–small cell lung cancer…
SupplementPublication Exclusive

Perspectives from ASCO 2015: A HemOnc Today Special Report

HemOnc Today, July 25, 2015
This year’s ASCO Annual Meeting featured the theme “Illumination and Innovation: Transforming Data into Learning.”As such, meeting…
Mary Reid In the Journals

Smoking after lung cancer diagnosis reduces survival

July 20, 2015
Patients with lung cancer who quit smoking at or after their diagnosis had better survival than patients who continued using tobacco after diagnosis…
Elyse R. Park, PhD, MPH In the Journals

PCP intervention can improve smoking cessation following lung cancer screening

July 20, 2015
Individuals who undergo lung cancer screening are more likely to quit smoking if their cessation intervention originated from their primary care…
Richard Pazdur, MD FDA approvals

FDA approves Iressa for EGFR-mutated NSCLC

July 13, 2015
The FDA today announced the approval of gefitinib for the first-line treatment of patients with metastatic non–small cell lung cancer whose…

What are the symptoms of lung cancer?

July 13, 2015
Lung cancer is the leading cause of cancer mortality in the United States, and it is responsible for more deaths than colon, prostate, ovarian and…
Ben Creelan, MD CommentaryPublication Exclusive

PD-1 antibodies a ‘big leap forward’ for NSCLC

HemOnc Today, July 10, 2015
Benjamin C. Creelan, MD
The 3-month median difference in OS seen in the trial by Paz-Ares and colleagues is outstanding.Since docetaxel was approved in 1999, there has been…
FDA News

ODAC discusses necitumumab for squamous NSCLC but takes no action

July 9, 2015
An FDA advisory committee today generally expressed support for the approval of necitumumab for the first-line treatment of patients with locally…
In the Journals

Annual low-dose CT screening limits unnecessary surgery in patients with nonsolid lung nodules

July 6, 2015
Nonsolid lung nodules can be safely monitored with yearly CT screenings, according to study results.Researchers said the findings may free patients…
More Headlines »
morganatic-roan morganatic-roan